Bitdefender and OVHcloud Partner to Deliver Sovereign Cybersecurity to European Businesses
7.10.2025 10:00:00 CEST | Business Wire | Press Release
Bitdefender, a European-based company and a global cybersecurity leader, today announced a strategic partnership with OVHcloud, Europe’s leading cloud provider, to host its advanced cybersecurity platform on OVHcloud services in France. The partnership delivers sovereign cybersecurity ensuring customer and configuration data, security events, telemetry is never accessible, transferred, or processed outside the European Union (EU).
The integration enables organizations to incorporate advanced cybersecurity capabilities to protect their operations and comply with rigorous French and EU regulations, while maintaining full control over data access and use.
At the core of the initiative is Bitdefender GravityZone, a comprehensive unified security, risk analytics, and compliance platform, hosted on the OVHcloud SecNumCloud service. GravityZone provides advanced endpoint protection (EPP), endpoint detection and response (EDR), extended detection and response (XDR), and cloud-native security, delivering end-to-end coverage across the entire attack chain. while offering deep context for detections that seamlessly extend to Bitdefender Managed Detection and Response (MDR) services.
OVHcloud SecNumCloud solutions, powered by data centers located across France (Roubaix, Gravelines, and Strasbourg), are designed to meet the highest standards for storing sensitive and critical information. They are qualified by the French Cybersecurity Agency (ANSSI) under its SecNumCloud framework—meeting over 360 technical, organizational, and legal requirements—to ensure robust security and full immunity from extraterritorial laws. They are suited for hosting sensitive data such as state records, patents, intellectual property, and critical datasets for artificial intelligence.
“We provide a secure and sovereign infrastructure that meets the highest French cybersecurity standards, and enables Bitdefender to deliver its proven cybersecurity suite, the same one that protects OVHcloud as a customer,” said Julien Levrard, CISO, at OVHcloud. “We are proud to collaborate with Bitdefender to bring sovereign, European security to organizations across the region. Together, we help businesses innovate and operate securely with confidence through the combined technologies and expertise of two trusted European leaders.”
This focus on security and transparency comes at a time when compliance challenges are mounting. A recent Bitdefender survey found that 35% of IT and security professionals in France reported being pressured to stay silent on breaches, even when they believed the incidents should have been disclosed. The finding highlights how growing regulatory requirements and compliance pressures across the EU are shaping how organizations handle cybersecurity incidents.
Against this backdrop, the partnership supports public and private organizations of all sizes across the EU that must meet strict data residency or sovereignty requirements. It is particularly relevant for sectors such as financial services, healthcare, education, critical infrastructure, energy, and manufacturing. In addition, it also enhances Bitdefender’s channel ecosystem, enabling partners and managed service providers (MSPs) to deliver EU-hosted GravityZone on OVHcloud SecNumCloud to customers with data residency requirements and manage those environments on their behalf.
“Businesses across Europe need security solutions that deliver advanced threat prevention, protection, detection, and response without sacrificing data sovereignty,” said Andrei Florescu, president and general manager of Bitdefender Business Solutions Group. “Partnering with OVHcloud delivers this, giving regulated industries the confidence to adopt leading-edge cybersecurity while maintaining full control over how their data is stored, processed, and secured. With GravityZone on OVHcloud SecNumCloud infrastructure, customers know their data remains within the EU. They also gain an easier path to compliance for GDPR, NIS2, DORA, and other regulations.”
For more information about the Bitdefender and OVHcloud partnership, visit here.
About OVHcloud
OVHcloud is a global cloud player and the leading European cloud provider operating over 450,000 servers within 44 data centers across 4 continents to reach 1.6 million customers in over 140 countries. Spearheading a trusted cloud and pioneering a sustainable cloud with the best performance-price ratio, the Group has been leveraging for over 20 years an integrated model that guarantees total control of its value chain: from the design of its servers to the construction and management of its data centers, including the orchestration of its fiber-optic network. This unique approach enables OVHcloud to independently cover all the uses of its customers so they can seize the benefits of an environmentally conscious model with a frugal use of resources and a carbon footprint reaching the best ratios in the industry. OVHcloud now offers customers the latest-generation solutions combining performance, predictable pricing, and complete data sovereignty to support their unfettered growth. For more information: www.ovhcloud.com
About Bitdefender
Bitdefender is a cybersecurity leader delivering best-in-class threat prevention, detection, and response solutions worldwide. Guardian over millions of consumers, enterprises, and government environments, Bitdefender is one of the industry’s most trusted experts for eliminating threats, protecting privacy, digital identity and data, and enabling cyber resilience. With deep investments in research and development, Bitdefender Labs discovers hundreds of new threats each minute and validates billions of threat queries daily. The company has pioneered breakthrough innovations in antimalware, IoT security, behavioral analytics, and artificial intelligence and its technology is licensed by more than 180 of the world’s most recognized technology brands. Founded in 2001, Bitdefender has customers in 170+ countries with offices around the world. For more information, visit https://www.bitdefender.com.
Trusted. Always.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007915500/en/
Contacts
Steve Fiore
Bitdefender
1-954-776-6262
sfiore@bitdefender.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom